OPKO Health Files 13D/A Amendment for GeneDx Holdings

TL;DR

OPKO Health updated its GeneDx stake filing on 7/26. Watch for potential moves.

AI Summary

OPKO Health, Inc. has filed an amendment to its Schedule 13D, indicating a change in its beneficial ownership of GeneDx Holdings Corp. as of July 26, 2024. The filing details OPKO Health's holdings and intentions regarding GeneDx.

Why It Matters

This filing provides insight into the significant stake and potential influence OPKO Health, Inc. holds over GeneDx Holdings Corp., which could impact GeneDx's strategic direction and shareholder value.

Risk Assessment

Risk Level: medium — Changes in beneficial ownership filings can signal shifts in control or strategy, potentially impacting stock price and requiring investor attention.

Key Players & Entities

• OPKO HEALTH, INC. (company) — Filing entity
• GeneDx Holdings Corp. (company) — Subject company
• Sema4 Holdings Corp. (company) — Former name of GeneDx Holdings Corp.
• CM Life Sciences, Inc. (company) — Former name of GeneDx Holdings Corp.
• Opko Health, Inc. (company) — Former name of OPKO HEALTH, INC.
• eXegenics Inc (company) — Former name of OPKO HEALTH, INC.

FAQ

Key Financial Figures

• $0.0001 — suer) Class A Common Stock, par value $0.0001 per share (Title of Class of Securiti
• $28.00 — the open market at prices ranging from $28.00 to $34.66 per share for an aggregate sa
• $34.66 — market at prices ranging from $28.00 to $34.66 per share for an aggregate sale price o
• $11,350,499 — n aggregate sale price of approximately $11,350,499. ITEM 5. Interest in Securities of t
• $26.4607 — the open market at prices ranging from $26.4607 to $34.66 per share for an aggregate sa
• $13,807,784 — n aggregate sale price of approximately $13,807,784. The following table sets forth the inf

Filing Documents

• opk20240725_sc13da.htm (SC 13D/A) — 61KB
• 0001437749-24-023645.txt ( ) — 63KB

is amended by adding the following paragraph to the end of the item

Item 4 is amended by adding the following paragraph to the end of the item: In a series of transactions between July 5, 2024 and July 26, 2024, OPKO sold a total of 346,118 shares of GeneDx Common Stock on the open market at prices ranging from $28.00 to $34.66 per share for an aggregate sale price of approximately $11,350,499. ITEM 5. Interest in Securities of the Issuer.

is deleted in its entirety and replaced with the following text

Item 5 is deleted in its entirety and replaced with the following text: (a) The Company's beneficial ownership of GeneDx Common Stock is as set forth in the table below: Name and Title of Beneficial Owner Number of Outstanding Shares Beneficially Owned Percentage of Outstanding Common Shares (1) OPKO Health, Inc. 3,123,403 11.94% ______________ (1) Based on 26,150,866 shares of GeneDx Common Stock of the Issuer outstanding on April 24, 2024, as set forth in the Issuer's DEF14A filed with the SEC on April 29, 2024. (b) Items 7-10, inclusive, set forth on the cover page to this Amendment are hereby incorporated by reference in this Item 5. (c) In the last 60 days prior to the filing of this Amendment No. 4, OPKO sold a total of 435,200 shares of GeneDx Common Stock on the open market at prices ranging from $26.4607 to $34.66 per share for an aggregate sale price of approximately $13,807,784. The following table sets forth the information with regard to GeneDx Common Stock sold by OPKO on the open market in the last 60 days. Date Shares of Common Stock Aggregate Purchase Price Price Per Share 7/1/24 50,000 $ 1,331,669 $ 26.6340 7/2/24 25,000 $ 728,095 $ 29.1238 7/3/24 14,082 $ 397,491 $ 28.2269 7/5/24 36,118 $ 1,020,015 $ 28.2412 7/17/24 25,000 $ 823,187 $ 32.9275 7/19/24 25,000 $ 807,250 $ 32.29 7/22/24 50,000 $ 1,630,422 $ 32.6088 7/23/24 75,000 $ 2,509,248 $ 33.4566 7/24/24 75,000 $ 2,529,102 $ 33.7214 7/26/24 60,000 $ 2,031,255 $ 33.8543 (d) Except as described herein, no other person is known by OPKO to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, any shares of the Issuer beneficially owned by them. (e) Not applicable. CUSIP No. 81663L200 Schedule 13D PAGE 4 of 4

SIGNATURES

SIGNATURES After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. OPKO Health, Inc. Dated: July 26, 2024 By: /s/ Steven D. Rubin Name: Steven D. Rubin Title: Executive Vice President - Administration

View Full Filing

View this SC 13D/A filing on SEC EDGAR